Engineered liposomes targeting the gut-CNS Axis for comprehensive therapy of spinal cord injury

J Control Release. 2021 Mar 10:331:390-403. doi: 10.1016/j.jconrel.2021.01.032. Epub 2021 Jan 22.

Abstract

Effective curative therapies for spinal cord injury (SCI), which is often accompanied by intestinal complications, are lacking. Potential therapeutic targets include astrocytes and their enteric nervous system counterpart, enteric glial cells (EGCs). Based on shared biomarkers and similar functions of both cell types, we designed an orally administered targeted delivery system in which the neuropeptide apamin, stabilized by sulfur replacement with selenium, was adopted as a targeting moiety, and the liposome surface was protected with a non-covalent cross-linked chitosan oligosaccharide lactate layer. The system effectively permeated through oral absorption barriers, targeted local EGCs and astrocytes after systemic circulation, allowing for comprehensive SCI therapy. Given the involvement of the gut-organ axis in a growing number of diseases, our research may shed light on new aspects of the oral administration route as a bypass for multiple interventions and targeted therapy.

Keywords: Astrocytes; Enteric glial cells; Gut-CNS axis; Oral delivery; Spinal cord injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytes
  • Humans
  • Liposomes*
  • Neuroglia
  • Spinal Cord
  • Spinal Cord Injuries* / drug therapy

Substances

  • Liposomes